Clinical trial NCT00563121 - References

Retinopathy of Prematurity — VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V

Citation(s)

•   Cooke RW, Drury JA, Mountford R, Clark D
  Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1712-5. doi: 10.1167/iovs.03-1303.
•   Gaynon MW
  Rethinking STOP-ROP: is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP. Retina. 2006 Sep;26(7 Suppl):S18-23. doi: 10.1097/01.iae.0000244292.86627.1e.
•   Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE
  Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8. doi: 10.1073/pnas.101113998. Epub 2001 May 1.
•   Itakura H, Kishi S, Kotajima N, Murakami M
  Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology. 2004 Oct;111(10):1880-4. doi: 10.1016/j.ophtha.2004.03.035.
•   Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N
  Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000 Apr;156(4):1337-44. doi: 10.1016/S0002-9440(10)65004-3.
•   Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Theisl A, Barth A, Aigner R, Haas A
  Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous. Mol Vis. 2006 Oct 2;12:1143-7.
•   Modanlou HD, Gharraee Z, Hasan J, Waltzman J, Nageotte S, Beharry KD
  Ontogeny of VEGF, IGF-I, and GH in neonatal rat serum, vitreous fluid, and retina from birth to weaning. Invest Ophthalmol Vis Sci. 2006 Feb;47(2):738-44. doi: 10.1167/iovs.05-1046.
•   Multicenter trial of cryotherapy for retinopathy of prematurity
  Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1988 Apr;106(4):471-9. doi: 10.1001/archopht.1988.01060130517027.
•   Phelps DL; ETROP Cooperative Group
  The Early Treatment for Retinopathy of Prematurity study: better outcomes, changing strategy. Pediatrics. 2004 Aug;114(2):490-1. doi: 10.1542/peds.114.2.490. No abstract available.
•   Pierce EA, Foley ED, Smith LE
  Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996 Oct;114(10):1219-28. doi: 10.1001/archopht.1996.01100140419009. Erratum In: Arch Ophthalmol 1997 Mar;115(3):427.
•   Yoo MH, Hyun HJ, Koh JY, Yoon YH
  Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7. doi: 10.1167/iovs.05-0376.

Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V

Details for clinical trial NCT00563121